Clinical Trials

LymphoidOther hematologic neoplasm

80 enrolled

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT06859424 2026-03-17

ACCELERATE

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

358 enrolled

Anemia, Refractory, with Excess of Blasts, Lymphoma, Myeloproliferative Disorders, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT07221500 2026-03-16

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

LymphoidOther hematologic neoplasm

100 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06510309 2026-03-13

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

33 enrolled

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT06510361 2026-03-13

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

35 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT07015242 2026-03-11

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

65 enrolled

Lymphoma

NCT03258567 2026-03-06

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT07030699 2026-03-06

ECLAT

27 enrolled

Lymphoma

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06698003 2026-03-05

A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1

LymphoidOther hematologic neoplasm

134 enrolled

Lymphoma, Leukemia, T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02974647 2026-02-27

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

83 enrolled

Lymphoma, Recurrence

NCT06854003 2026-02-20

BRAZAN

60 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT06563596 2026-02-19

Epco, Zanu, Ritux for R/R FL or MZL

45 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT04570423 2026-02-18

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Lymphoma

NCT06563505 2026-01-21

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

36 enrolled

Lymphoma

NCT07356245 2026-01-21

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

DermatologicLymphoidOther hematologic neoplasm

44 enrolled

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05464719 2026-01-12

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

30 enrolled

Lymphoma

NCT05929612 2026-01-09

A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

50 enrolled

Lymphoma

NCT02106988 2026-01-07

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Lymphoma

NCT07062627 2025-12-17

Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

12 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06218602 2025-12-16

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

Lymphoma

NCT07285590 2025-12-16

IMCL-2023

50 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT05977673 2025-12-08

FIL_Tisle-HL

28 enrolled

Hodgkin Disease, Lymphoma

NCT06986174 2025-12-05

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

30 enrolled

Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT07014319 2025-12-04

MALMBA

20 enrolled

Lymphoma

NCT05099471 2025-11-28

VIWA-1

80 enrolled

Lymphoma, Waldenstrom Macroglobulinemia, Neoplasms

NCT07254754 2025-11-28

LATE-R-GEL-23

45 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

20 enrolled

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT07126236 2025-08-17

REPIFIR

80 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03314974 2025-06-24

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

300 enrolled

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Burkitt Lymphoma, Leukemia, Plasma Cell, Lymphoma, Lymphoma, Follicular, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile, Primary Myelofibrosis

NCT05346809 2025-06-08

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

39 enrolled

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT06680661 2025-06-04

ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis